mesna (Rx)

Brand and Other Names:Mesnex

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

injectable solution

  • 100mg/mL

tablet

  • 400mg

Prevention of Ifosfamide Induced Hemorrhagic Cystitis

240 mg/m² (if receiving 1.2 g/m² ifosfamide dose) IVP 15 minutes before & 4 & 8 hours after ifosfamide admin OR  

240 mg/m² (if receiving 1.2 g/m² ifosfamide dose) IVP 15 minutes before & 480 mg/m² of mesna tablets PO 2 & 6 hours after ifosfamide admin

Adjust dose accordingly if ifosfamide dose changes

Also given by alternative IVP regimens, intermittent infusion or continuous infusion-see IV Info

Prevention of Cyclophosphamide Induced Hemorrhagic Cystitis (Off-label)

20% of cyclophosphamide dose when injected, 4 and 8 hours after each dose

Safety & efficacy not established

Next:

Adverse Effects

>10%

Nausea

Vomiting

Anorexia

Asthenia

Fatigue

Fever

Abdominal pain

Constipation

Anemia

Granulocytopenia

Leukopenia

Thrombocytopenia

Alopecia

1-10%

Anxiety

Confusion

Dizziness

Headache

Insomnia

Pain

Somnolence

Chest pain

Edema

Flushing

Tachycardia

Cough

Dyspnea

Pneumonia

Diarrhea

Hematuria

Hypokalemia

Back pain

Dehydration

Injection site reaction

Pallor

Previous
Next:

Warnings

Contraindications

Hypersensitivity to mesna or other thiol compounds

Cautions

Does NOT prevent nephrotoxicity, myelosuppression, or neurotoxicity

Will not prevent hemorrhagic cystitis in all patients; examine morning urine specimen for hematuria prior to ifosfamide or cyclophosphamide treatment

Does not prevent or improve other toxicities associated with ifosfamide or cyclophosphamide

If patient vomits within 2 hr after PO dose, repeat dose or give IV

Mesna does not prevent thrombocytopenia-related hematuria

Hypersensitivity

  • May cause systemic hypersensitivity reactions, including anaphylaxis; these reactions may include fever, cardiovascular symptoms (hypotension, tachycardia), acute renal impairment, hypoxia, respiratory distress, urticaria, angioedema, laboratory signs of disseminated intravascular coagulation, hematological abnormalities, increased liver enzymes, nausea, vomiting, arthralgia, and myalgia
  • These reactions may occur with first exposure or after several months of exposure; monitor for signs or symptoms; discontinue therapy and provide supportive care
  • This drug is a thiol compound, eg, a sulfhydryl (SH) group-containing organic compound; hypersensitivity reactions to mesna and to amifostine, another thiol compound, reported; it is not clear whether patients who experienced an adverse reaction to a thiol compound are at increased risk for a hypersensitivity reaction to this drug

Dermatologic toxicity

  • Drug rash with eosinophilia and systemic symptoms and bullous and ulcerative skin and mucosal reactions, consistent with Stevens-Johnson syndrome or toxic epidermal necrolysis reported
  • Therapy may cause skin and mucosal reactions characterized by urticaria, rash, erythema, pruritus, burning sensation, angioedema, periorbital edema, flushing, and stomatitis
  • These reactions may occur with first exposure or after several months of exposure; discontinue therapy and provide supportive care

Benzyl alcohol toxicity

  • Serious adverse reactions including fatal reactions and “gasping syndrome” occurred in premature neonates and low-birth-weight infants who received benzyl alcohol dosages of 99 to 234 mg/kg/day (blood levels of benzyl alcohol were 0.61 to 1.378 mmol/L)
  • Symptoms associated with “gasping syndrome” and other potential adverse reactions include gradual neurological deterioration, seizures, intracranial hemorrhage, hematological abnormalities, skin breakdown, hepatic and renal failure, hypotension, bradycardia, and cardiovascular collapse
  • Premature neonates and low-birth-weight infants may be more likely to develop these reactions because they may be less able to metabolize benzyl alcohol; the minimum amount of benzyl alcohol at which toxicity may occur is not known
  • Injection formulation contains 10.4 mg/mL of preservative benzyl alcohol; avoid use in premature neonates and low-birth-weight infants; tablets do not contain benzyl alcohol
Previous
Next:

Pregnancy & Lactation

Pregnancy

Drug is used in combination with ifosfamide or other cytotoxic agents; ifosfamide can cause fetal harm when administered to a pregnant woman; refer to the ifosfamide prescribing information for more information on use during pregnancy

Mesna injection contains the preservative benzyl alcohol; because benzyl alcohol is rapidly metabolized by a pregnant woman, benzyl alcohol exposure in the fetus is unlikely

Animal data

  • In embryo-fetal development studies, oral administration of mesna to pregnant rats (500, 1000, 1500, and 2000 mg/kg) and rabbits (500 and 1000 mg/kg) during period of organogenesis revealed no adverse developmental outcomes at doses approximately 10 times maximum recommended total daily human equivalent dose based on body surface area

Pregnancy testing

  • Verify pregnancy status of females of reproductive potential prior to initiation of drug in combination with ifosfamide

Contraception

  • Females: Advise females of reproductive potential to use effective contraception during treatment in combination with ifosfamide and for 6 months after last dose
  • Males: Advise males with female partners of reproductive potential to use effective contraception during treatment in combination with ifosfamide and for 3 months after last dose

Lactation

Used in combination with ifosfamide or other cytotoxic agents; ifosfamide is excreted in breast milk; refer to the ifosfamide prescribing information for more information on use during lactation; there are no data on presence of mesna in human or animal milk, effect on breastfed child, or on milk production

Formulation contains preservative benzyl alcohol; because benzyl alcohol is rapidly metabolized by a lactating woman, benzyl alcohol exposure in breastfed infant is unlikely; because of potential for serious adverse reactions in breastfed child, advise lactating women not to breastfeed during treatment and for 1 week after last dose

Pregnancy Categories

A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

NA: Information not available.

Previous
Next:

Pharmacology

Mechanism of Action

Oxidized to dimesna in the blood, and is in turn reduced back to mesna in the kidney; synthetic sulfhydryl (thiol) compound binds & detoxifies ifosfamide metabolite acrolein in bladder/kidney

Mesna disulfide (dimesna): Inert metabolite

Pharmacokinetics

Bioavailability: 45-79 %

Protein Bound: 69-75% (mesna plus dimesna)

Metabolism: Kidney

Metabolites: Mesna disulfide

Excretion: Urine (18-32% as mesna; 33% as dimesna)

Distribution: Does not penetrate tissue

Half-life: 0.36 hr (Mesna); 1.17 hr (dimesna)

Peak plasma time: 4 hr (mesna); 3 hr (dimesna)

Peak plasma concentration: 3.3 mcg/mL (PO; mesna); 7.3 mcg/mL (PO; dimesna)

Previous
Next:

Administration

IV Incompatibilities

Additive: carboplatin, cisplatin, ifosfamide/epirubicin

Syringe: ifosfamide/epirubicin

Y-site: amphotericin B cholesteryl sulfate

IV Compatibilities

Solution: D5W, NS, LR, D5/½NS

Additive: ifosfamide, hydroxyzine

Syringe: ifosfamide

Y-site (partial list): allopurinol, docetaxel, gemcitabine, doxorubicin liposomal, linezolid, granisetron, ondansetron, vinorelbine

IV Preparation

Reconstitute w/ D5W, NS, dextrose/saline or LR to a final concentration of 20 mg/mL

IV Administration

IVP: bolus 15 min before ifosfamide

Intermittent infusion over 15-30 min

Continuous Infusion: may be added to ifosfamide/cyclophosphamide in infusion bag

  • Additive compatibility w/ cyclophosphamide shown only in D5W & LR

Multiple protocols exist; check institutional guidelines

Storage

Store unopened vials at 20-25°C (68-77°F)

Opened ampoules will oxidize to dimesna upon exposure to air

Previous
Next:

Images

BRAND FORM. UNIT PRICE PILL IMAGE
Mesnex oral
-
400 mg tablet
mesna intravenous
-
100 mg/mL vial
mesna intravenous
-
100 mg/mL vial
mesna intravenous
-
100 mg/mL vial
mesna intravenous
-
100 mg/mL vial
mesna intravenous
-
100 mg/mL vial
mesna intravenous
-
100 mg/mL vial
mesna intravenous
-
100 mg/mL vial
Mesnex intravenous
-
100 mg/mL vial

Copyright © 2010 First DataBank, Inc.

Previous
Next:

Patient Handout

Select a drug:
Patient Education
mesna oral

MESNA - ORAL

(MESS-na)

COMMON BRAND NAME(S): Mesnex

USES: This medication is used to reduce the risk of bleeding in the bladder (hemorrhagic cystitis), which is a very serious side effect of treatment with a cancer chemotherapy drug called ifosfamide. Mesna helps to protect the lining of the bladder against damage from ifosfamide. The body breaks down ifosfamide to form a product that can harm the bladder, and mesna works by making this product less harmful. However, mesna does not change ifosfamide's anti-cancer effects.

HOW TO USE: Read the Patient Information Leaflet if available from your pharmacist before you start taking mesna and each time you get a refill. If you have any questions, ask your doctor or pharmacist.Take this medication by mouth. Follow the dosing schedule as directed by your doctor. The dosage is based on your body size and your dose of ifosfamide (or cyclophosphamide).While taking this medication, drink at least a quart (4 cups or 1 liter) of liquid each day unless directed otherwise by your doctor. Doing so will also help to reduce the bladder side effects from the chemotherapy drug.Tell your doctor right away if you vomit within 2 hours of taking a dose. Your doctor will determine if you should repeat the dose or receive mesna by injection into a vein.Mesna is very effective in reducing the risk of hemorrhagic cystitis in most patients. However, it may not work in a small number of patients. Tell your doctor right away if you notice that your urine is pink, red, or bloody.

SIDE EFFECTS: Headache, flushing, dizziness, drowsiness, nausea, vomiting, loss of appetite, diarrhea, constipation, sensitive skin, or flu-like symptoms (such as sore throat, cough, body aches) may occur. If any of these effects last or get worse, tell your doctor or pharmacist promptly.Remember that this medication has been prescribed because your doctor has judged that the benefit to you is greater than the risk of side effects. Many people using this medication do not have serious side effects.Tell your doctor right away if you have any serious side effects, including: fast heartbeat, swelling ankles/feet, muscle weakness.Get medical help right away if you have any very serious side effects, including: chest pain.A very serious allergic reaction to this drug is rare. However, get medical help right away if you notice any symptoms of a serious allergic reaction, including: fever, swollen lymph nodes, rash, itching/swelling (especially of the face/tongue/throat), severe dizziness, trouble breathing.This is not a complete list of possible side effects. If you notice other effects not listed above, contact your doctor or pharmacist.In the US -Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 or at www.fda.gov/medwatch.In Canada - Call your doctor for medical advice about side effects. You may report side effects to Health Canada at 1-866-234-2345.

PRECAUTIONS: Before taking mesna, tell your doctor or pharmacist if you are allergic to it; or if you have any other allergies. This product may contain inactive ingredients, which can cause allergic reactions or other problems. Talk to your pharmacist for more details.Before using this medication, tell your doctor or pharmacist your medical history.This drug may make you dizzy or drowsy. Alcohol or marijuana (cannabis) can make you more dizzy or drowsy. Do not drive, use machinery, or do anything that needs alertness until you can do it safely. Limit alcoholic beverages. Talk to your doctor if you are using marijuana (cannabis).Before having surgery, tell your doctor or dentist about all the products you use (including prescription drugs, nonprescription drugs, and herbal products).Tell your doctor if you are pregnant or plan to become pregnant. Since mesna is used with a chemotherapy drug, you should not become pregnant during treatment because the chemotherapy drug may harm an unborn baby. Ask about reliable forms of birth control while using this medication and chemotherapy. If you become pregnant, talk to your doctor right away about the risks and benefits of mesna and the chemotherapy drug.It is unknown if this drug passes into breast milk. Since mesna is given with a chemotherapy drug, breast-feeding while using this medication is not recommended during treatment and for 1 week after the last dose of mesna or the chemotherapy drug. Consult your doctor before breast-feeding.

DRUG INTERACTIONS: Drug interactions may change how your medications work or increase your risk for serious side effects. This document does not contain all possible drug interactions. Keep a list of all the products you use (including prescription/nonprescription drugs and herbal products) and share it with your doctor and pharmacist. Do not start, stop, or change the dosage of any medicines without your doctor's approval.This medication may interfere with certain lab tests (such as urine ketone test), possibly causing false test results. Make sure lab personnel and all your doctors know you use this drug.

OVERDOSE: If someone has overdosed and has serious symptoms such as passing out or trouble breathing, call 911. Otherwise, call a poison control center right away. US residents can call their local poison control center at 1-800-222-1222. Canada residents can call a provincial poison control center.

NOTES: Do not share this medication with others.This medication does not protect you from other side effects of ifosfamide. Consult your doctor or pharmacist for more information on how to manage other side effects.Small amounts of blood in the urine cannot be seen without a microscope. A lab test to check for blood in your urine should be done before each dose of ifosfamide. Keep all medical and lab appointments. Consult your doctor for more details.

MISSED DOSE: It is important to take each dose of this medication as scheduled. If you miss a dose, take it as soon as you remember and contact your doctor for further instructions. Do not double the dose to catch up.

STORAGE: Store at room temperature away from light and moisture. Do not store in the bathroom. Keep all medications away from children and pets.Do not flush medications down the toilet or pour them into a drain unless instructed to do so. Properly discard this product when it is expired or no longer needed. Consult your pharmacist or local waste disposal company.

Information last revised August 2023. Copyright(c) 2023 First Databank, Inc.

IMPORTANT: HOW TO USE THIS INFORMATION: This is a summary and does NOT have all possible information about this product. This information does not assure that this product is safe, effective, or appropriate for you. This information is not individual medical advice and does not substitute for the advice of your health care professional. Always ask your health care professional for complete information about this product and your specific health needs.

Previous
Next:

Formulary

FormularyPatient Discounts

Adding plans allows you to compare formulary status to other drugs in the same class.

To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

Adding plans allows you to:

  • View the formulary and any restrictions for each plan.
  • Manage and view all your plans together – even plans in different states.
  • Compare formulary status to other drugs in the same class.
  • Access your plan list on any device – mobile or desktop.

The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

Tier Description
1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
NC NOT COVERED – Drugs that are not covered by the plan.
Code Definition
PA Prior Authorization
Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
QL Quantity Limits
Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
ST Step Therapy
Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
OR Other Restrictions
Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
Additional Offers
Email to Patient

From:

To:

The recipient will receive more details and instructions to access this offer.

By clicking send, you acknowledge that you have permission to email the recipient with this information.

Email Forms to Patient

From:

To:

The recipient will receive more details and instructions to access this offer.

By clicking send, you acknowledge that you have permission to email the recipient with this information.

Previous
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.